Orgenesis Insiders

ORGSDelisted Stock  USD 1.22  0.31  20.26%   
Orgenesis employs about 146 people. The company is managed by 12 executives with a total tenure of roughly 341 years, averaging almost 28.0 years of service per executive, having 12.17 employees per reported executive. Breaking down Orgenesis' management performance can provide insight into the firm performance.
Victor Miller  Executive
Chief Officer
Osher Rheinisch  Executive
General Officer
  
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price.

Orgenesis Management Team Effectiveness

The company has return on total asset (ROA) of (0.3008) % which means that it has lost $0.3008 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.2725) %, meaning that it created substantial loss on money invested by shareholders. Orgenesis' management efficiency ratios could be used to measure how well Orgenesis manages its routine affairs as well as how well it operates its assets and liabilities.

Orgenesis Workforce Comparison

Orgenesis is regarded third in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 1,144. Orgenesis retains roughly 146 in number of employees claiming about 13% of equities under Health Care industry.

Orgenesis Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Orgenesis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Orgenesis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Orgenesis insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Orgenesis Notable Stakeholders

An Orgenesis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Orgenesis often face trade-offs trying to please all of them. Orgenesis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Orgenesis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.

About Orgenesis Management Performance

The success or failure of an entity such as Orgenesis often depends on how effective the management is. Orgenesis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Orgenesis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Orgenesis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people.
The data published in Orgenesis' official financial statements typically reflect Orgenesis' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Orgenesis' quantitative information. For example, before you start analyzing numbers published by Orgenesis accountants, it's essential to understand Orgenesis' liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Please note, the imprecision that can be found in Orgenesis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Orgenesis. Check Orgenesis' Beneish M Score to see the likelihood of Orgenesis' management manipulating its earnings.

Orgenesis Workforce Analysis

Traditionally, organizations such as Orgenesis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Orgenesis within its industry.

Orgenesis Manpower Efficiency

Return on Orgenesis Manpower

Revenue Per Employee3.6K
Revenue Per Executive44.2K
Net Loss Per Employee444.6K
Net Loss Per Executive5.4M
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price.
Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Other Consideration for investing in Orgenesis OTC Stock

If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamental Analysis
View fundamental data based on most recent published financial statements
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges